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Bile duct cells and hepatocytes differentiate from the same hepatic progenitor cells. To investigate the possible association of viral
hepatitis B and C with intrahepatic cholangiocarcinoma (ICC), we conducted a retrospective case–control study using univariate and
multivariate logistic analyses to identify risk factors for ICC. Besides hepatic lithiasis (25.6%; Po0.001), seropositivity for hepatitis B
surface antigen (37.5% of all ICC patients; odds ratio (OR) ¼4.985, Po0.001) and seropositivity for hepatitis C antibodies (13.1%;
OR¼2.709; P¼0.021) are the primary independent risk factors for ICC. Cirrhosis exerted synergic effects on the development of
ICC. We compared the age distributions of viral-hepatitis associated ICC to that of viral hepatitis-associated hepatocellular carcinoma
(HCC). The mean age of ICC patients with viral hepatitis B (56.4±11.1 years) were 9 years younger than that of ICC patients with
viral hepatitis C (65.6±9.17 years), similar to that observed in HCC. The incidence ratio of HCC:ICC:CHC (combined
hepatocellular cholangiocarcinoma) in our population was 233:17:1 consistent with the theoretic ratio of hepatocyte number to
cholangiocyte number in the liver. Our findings indicated that both viral hepatitis-associated ICC and HCC shared common disease
process for carcinogenesis and, possibly, both arose from the hepatic progenitor cells.
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Primary liver cancer is one of the most common cancers in the
world. Intrahepatic cholangiocarcinoma (ICC) is the second most
frequent primary liver cancer after hepatocellular carcinoma
(HCC), which accounts for more than 80% of these cases.
Combined hepatocellular cholangiocarcinoma (CHC) is also
occasionally found, but is relatively rare with a frequency of
B1% of the total primary liver cancers (Bhagat et al, 2006).
Hepatocellular carcinoma is strongly associated with chronic viral
hepatitis B and C and liver cirrhosis. In addition, other forms of
chronic inflammation of the liver including alcoholic liver disease,
hemochromomatosis and congenital and acquired metabolic
diseases also contribute to the development of HCC (El-Serag
and Rudolph, 2007). On the other hand, the etiology of ICC
remains unclear (Shaib et al, 2007; Welzel et al, 2007; Blechacz and
Gores, 2008b). Though several risk factors, including hepatolithia-
sis, inflammatory bile duct disease (sclerosing cholangitits), liver
fluke infection and anatomical abnormalities associated with
biliary tract inflammation have been described, most occur in
absence of known etiological factors (Ben-Menachem, 2007;
Blechacz and Gores, 2008b).
The findings of CHC, particularly in patients of viral hepatitis B
or C, indicate a common origin and/or shared pathogenic
mechanisms for both HCC and ICC (Bhagat et al, 2006). Though
several environmental carcinogenesis models of cholangiocarcino-
ma including infestation with liver flukes, especially the species
Opisthorchis viverrini and Clonorchis senensis, have been estab-
lished in animals, neither the etiological correlation nor any
preclinical models associated viral hepatitis with ICC are available
(Blechacz and Gores, 2008a).
Herein, we present our retrospective case–control studies on the
association of viral hepatitis B and C with ICC. As at the time of
HCC diagnosis, HCC patients with viral hepatitis B is B10 years
younger than those with viral hepatitis C, we re-evaluated the
association of viral hepatitis-related ICC with viral hepatitis-HCC.
We compared the incidence and age distribution of ICC to that of
HCC in patients with chronic viral hepatitis B or C, thereby
contributing to our understanding of the pathogenesis of ICC and
indirectly to that of HCC.
MATERIALS AND METHODS
Study subjects
The institutional ethics committee approved all protocols applied
in this study. We selected consecutive cases of diagnosed ICC
among inpatients who were admitted between 1991 and 2005 to
our hospital, the Chang Gung Memorial Hospital at the Lin-Ko
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pathological diagnosis of ICC, with complete medical records for
serum HBsAg (hepatitis B virus surface antigen) and anti-HCV
(antibodies to hepatitis C virus), and pathological diagnosis,
ultrasonography or other imaging studies to evaluate cirrhosis.
Consequently, a total of 160 patients with ICC were included in this
study.
Moreover, 2498 patients with HCC diagnosed at the same
hospital during the same period from 1991 to 2005 were selected
for the comparison.
Hospital controls matched for sex and age to the ICC patients
were selected from individuals generally surveyed for any disease
in our hospital.
To calculate the incidences of ICC, HCC and CHC in our
country, we retrieved the case numbers of newly diagnosed ICC,
HCC and CHC in Taiwan during 2003–2005 from our government
cancer registration system (the Taiwan Cancer Registration System
2004–2006) (http://crs.cph.ntu.edu.tw).
Liver cirrhosis
The criteria for the diagnosis of cirrhosis were as follows: clinical
manifestations of chronic hepatitis with portal hypertension and/
or hepatic decompensation, laboratory tests and hepatic ultra-
sonography. Characteristic signs included portal hypertension
(varices, thrombocytopenia or splenomegaly) and/or signs of
hepatic decompensation (jaundice, prolonged prothrombin time
and ascites).
Laboratory tests
Blood samples were tested for the surface antigens of hepatitis B
virus (HBsAg) and antibodies against hepatitis C virus (anti-HCV)
using enzyme-linked immunosorbent assays (Abbott Laboratories,
North Chicago, IL, USA).
Statistical methods
Independence tests were performed using unpaired t-test for
continuous variables and w-square or Fisher’s exact test for
categorical variables. We calculated the OR (odds ratio), RR
(relative risk) and PPV (positive predictive value) of ICC.
We used univariate logistic regression to determine the variables
that predisposed to ICC, and then employed multivariate logistic
regression without intercept to select the most important variable.
For each factor in the different populations, we also used logistic
regression to estimate the OR and 95% CI (confidence interval) of
the population-attributable risk, which was calculated using the
OR of that factor and its prevalence in the control group.
RESULTS
Patient characteristics
We enrolled 160 consecutive patients of ICC and 160 age-matched
individuals as controls to search the risk factors for ICC (Table 1
and Figure 1).
Of the 160 ICC patients, 60 were seropositive for HBsAg (37.5%);
21 were seropositive for anti-HCV (13.1%), including seven cases
of seropositivity for both HBsAg and anti-HCV; 41 had
intrahepatic-duct stones (IHD stones) (25.6%); and 21 had
cirrhosis (25.6%) (Figure 1A). In the control group, 22 were
seropositive for HBsAg (13.8%); 10 were seropositive for anti-HCV
(6.3%) and none had IHD stone or cirrhosis (Figure 1B). In
addition, patients with gallstone were seen in both the ICC group
(18 patients, 11.3%) and the control group (22 patients, 13.8%)
(Table 1), whereas patients with IHD stones (41 patients, 25.6%),
cirrhosis (41 patients, 25.6%), and biliary parasite (C. sinensis)
(1 patients) were only found in the ICC group (Table 1).
Univariate analysis of the risk factors for ICC
As shown in Table 1, the sero-positive rates for HBsAg and anti-
HCV in the ICC group were significantly higher than those in the
control group (HBsAg: 37.5 vs 13.8%, Po0.001; and anti-HCV:
13.1 vs 6.3%, P¼0.038). In addition, the prevalence of IHD stones
and cirrhosis were also higher in ICC patients than in the controls
(IHD stones: 25.6 vs 0%. Po0.001; and cirrhosis: 25.6 vs 0%,
Table 1 Demographics and baseline clinical characteristics of ICC
patients and control cases
ICC (n¼160) Control (n¼160) P-value
Gender (male/female) 101/59 87/73 0.112
Age (mean±s.d., years) 61.5±12.0 61.0±12.2 0.765
HBsAg 60 (37.5%) 22 (13.8%) 0.000
Anti-HCV 21 (13.1%) 10 (6.3%) 0.038
Biliary stones
GB stones only 18 (11.3%) 22 (13.8%) 0.499
IHD stones 41 (25.6%) 0 0.000
Liver cirrhosis 41 (25.6%) 0 0.000
Biliary parasites 1 0 0.317
HBsAg¼seropositivity for hepatitis B surface antigen; Anti HCV¼seropositivity for
anti-hepatitis C virus antibody; GB¼gall bladder; IHD¼intrahepatic ducts. P-values
were determined by univariate logistic regression, w
2- test.
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Figure 1 Distribution of potential risk factors for ICC among the 160
ICC patients (A) and the 160 control cases (B). B¼ seropositivity for
HBsAg; C¼ seropositivity for anti-HCV antibody; Cirr¼ cirrhosis;
IHD¼ intrahepatic duct stone.
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stones or biliary parasite infection between the ICC and control
groups was not statistically significant (gallbladder stones: 11.3 vs
13.8%, P¼0.499; and biliary parasite infection: 0.6 vs 0%,
P¼0.317, respectively). It is worthy to mention that liver flukes,
especially clonorchiasis and opisthorchiasis, which are prevalence
in East and South Asia, have been proved to be the important
causes of ICC. In our series, only one case of ICC had liver fluke.
Low incidence of liver fluke infestation in our ICC patients could
be explained by low prevalence of clonorchiasis in the past 13 years
in Taiwan (o0.01% since 1995), though it was once very prevalent
(about 1.5% in 1969; 0.2% in 1993 (Epidemiology Report, Division
of Epidemiology, Department of Health, Taiwan, 1993; 9(5))).
To evaluate the contribution of each risk factor to ICC
development, the ORs were analysed (Table 2). Patients with viral
hepatitis B showed a 3.8-fold increase in the risk for ICC (95% CI:
2.17–6.53, Po0.001), and patients with viral hepatitis C showed a
2.3-fold increase in the risk for ICC (95% CI: 1.03–4.98, P¼0.038).
The PPV for ICC in the patients of viral hepatitis B and C were
18.13 10
 5 and 10.92 10
 5, respectively, which were also
Bthree-fold higher than that in our general population (the
prevalence of ICC in our population¼2.48 10
 5). As there were
no cases of cirrhosis or IHD stones in the control group, neither
the OR nor the PPV for ICC among patients of viral hepatitis B and
C could be determined.
Multiple logistic regression analysis
To determine the independent factor(s) in the development of ICC,
multiple logistic regression analysis was conducted. As shown in
Table 3, seropositivity for HBsAg, seroposivity for anti-HCV, and
the presence of IHD stones were independent factors associated
with ICC. Again, the OR’s for seropositivity for HBsAg and
seropositivity for anti-HCV were 4.985 (95% CI: 2.775–8.945,
Po0.001) and 2.709 (95% CI: 1.162–6.318, P¼0.021), respectively.
Synergistic effects of cirrhosis on the development of ICC
in patients who were seropositive for HBsAg or anti-HCV
Cirrhosis is always associated with chronic inflammation either
because of chronic B and/or chronic hepatitis C or because of bile
duct inflammation, and B90% of HCC cases were detected in
cirrhosis patients. Therefore, it is interesting to examine whether
cirrhosis played a synergistic role in ICC development in patients
with viral hepatitis B and/or C. Univariate logistic regression
analysis of the effects of cirrhosis on these patients with chronic
viral hepatitis showed that cirrhosis increased the risks for ICC by
2.5-, 3.2- and 12.6-fold in patients who were seropositive for
HBsAg (95% CI: 1.196–5.095, P¼0.015), anti-HCV (95% CI:
1.231–8.148, P¼0.017) and both HBsAg and anti-HCV (95% CI:
2.533–62.923, P¼0.002), respectively (Table 4).
Age distribution of ICC vs HCC patients
Strongly etiological association of chronic viral hepatitis and
cirrhosis with ICC is reminiscent of that of HCC in our population.
It is, therefore, tempting to speculate that viral hepatitis-associated
ICC may develop through a similar pathogenic process to that for
HCC development. Development of HCC in chronic viral hepatitis
is a long-term process, and HCC patients of viral hepatitis B are
usually about 10 years younger than HCC patients of viral hepatitis
C, probably because of difference in the onset age of chronic viral
hepatitis. If both viral associated HCC and ICC run through a
similar pathogenic process, they would share similar difference of
age distributions between patients with viral hepatitis B and C. To
examine this hypothesis, we analysed age distributions of ICC in 60
patients with viral hepatitis B and 21 patients with viral hepatitis C
(Table 5). Indeed, ICC patients with viral hepatitis B (56.4±11.1
years old) were about 9 years younger than ICC patients with viral
hepatitis C (65.6±9.2 years old). We then compared the results to
that of HCC in 2498 consecutive patients with HCC, who consulted
our hospital during the period when ICC case collection (Figure 2).
The mean age of HCC patients with viral hepatitis B (54.03±11.60
years) was about 9 years younger than that of HCC patients with
viral hepatitis C (62.63±9.55 years). To further compare the
details about onset age between ICC and HCC with the underlying
viral hepatitis B vs C, the profiles of age distribution for both ICC
and HCC were performed (Figure 2A and B). The profiles of age
distribution between ICC and HCC patients with viral hepatitis B
were basically consistent (Figure 2A). In addition, the profiles of
Table 2 Univariate analysis of risk factors at presentation that were
associated with the ICC (160 patients) and control (160 persons) groups
HBsAg Anti-HCV Cirrhosis IHD stones
Positive rate
ICC patients 37.5% 13.1% 25.6% 25.6%
Controls 13.8% 6.3% 0% 0%
Odds ratio 3.763 2.266 —
a —
a
P-value 0.000 0.038 0.000 0.000
PPV 18.13 10
 5 10.92 10
 5
95% CI 2.17–6.53 1.03–4.98 —
a —
a
PPV¼positive predictive value; HBsAg¼seropositivity for hepatitis B surface antigen;
anti-HCV¼seropositivity for anti-hepatitis C virus antibody; IHD¼intrahepatic duct.
P-values were determined using w
2 or Fisher’s exact test as any of the value o5. The
annular incidence of cholangiocarcinoma was 4.819 10
 5 in our general population.
PPV¼OD annular incidence.
aNo case of IHD stones or liver cirrhosis was observed in the control group.
Therefore, the odds ratio and 95% CI (confidence interval) could not be calculated.
Table 3 Multiple logistic regression analysis of risk factors for ICC
Odds ratio 95% CI P-value
HBsAg (1)
a 4.985 2.775–8.945 0.000
Anti-HCV (1)
a 2.709 1.162–6.318 0.021
IHD stone 4.810 2.626–8.015 0.000
Cirrhosis —
b —
b —
b
HBsAg¼seropositivity for hepatitis B surface antigen; anti-HCV¼seropositivity for
anti-hepatitis C virus antibody; IHD¼intrahepatic duct.
aVariable(s) entered in step 1: HBsAg, anti-HCVand IHD stones.
bNo case of liver
cirrhosis was found in the control group; therefore, the odds ratio and 95% CI
(confidence interval) could not be calculated.
Table 4 Logistic regression in 74 cases of viral associated ICC and the
synergistic effects of liver cirrhosis on viral hepatitis B and C
Risk factors
Additional
factors No. P-value
Odds
ratio 95% CI
HBsAg
With Cirrhosis 38 0.015* 2.468 1.196–5.095
Without 22
Anti-HCV
With Cirrhosis 11 0.017* 3.167 1.231–8.148
Without 10
HBsAg+Anti-HCV
With Cirrhosis 3 0.002* 12.625 2.533–62.923
Without 4
HBsAg¼seropositivity for hepatitis B surface antigen; Anti-HCV¼seropositivity for
anti-hepatitis C virus antibody; 95% CI¼95% confidence interval. *Po0.05 was
considered significant (two-sample t-test).
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C were consistent (Figure 2B). In contrast, the profiles of ICC and
HCC patients with viral hepatitis B were greatly diverse from that
of ICC and HCC patients with viral hepatitis C (Figure 2A vs B). In
other words, the profiles of age distributions of viral hepatitis-
associated ICC were consistent with those of viral hepatitis-
associated HCC, suggesting the implication of common disease
process for both viral hepatitis-associated ICC and HCC.
The incidence of HCC, ICC and combined HCC with ICC in
our population
Sharing common disease profiles for both viral hepatitis-asso-
ciated ICC and HCC including viral-hepatitis etiology, synergic
effects of cirrhosis and age distributions suggests the involvement
of similar long-term disease process, and even a common cell
origin for carcinogenesis. It is, therefore, intriguing to speculate
that the relative incidences for HCC and ICC and the CHC might
be related to the ratio of hepatocytes and cholangiocytes, both of
which were differentiated from the hepatic progenitor cells (oval
cells). We then calculated the relative incidences for HCC, ICC
and CHC in our population. We retrieved the annular incidence of
HCC, ICC and CHC from our national cancer registration
system (the Taiwan Cancer Registration System, 2004–2006)
(http://crs.cph.ntu.edu.tw). The new diagnosed cases of HCC,
ICC and CHC in our population during the period 2004–2006 were
26543 cases, 1949 cases and 114 cases, respectively. The case/
number ratio of HCC:ICC:CHC was 233:17:1, which was
consistent with the number ratio of hepatocytes to cholangiocytes
in the liver.
DISCUSSION
Though association of viral hepatitis B and C with ICC has been
documented (Wiwanitkit, 2005; Perumal et al, 2006; Shaib et al,
2007; Hsing et al, 2008; Zhou et al, 2008; El-Serag et al, 2009), the
role of viral hepatitis B and C in the development of ICC in viral
hepatitis endemic areas remains to be addressed. Herein, we not
only show a strong etiological association of viral hepatitis B and C
with ICC, but also provide circumstantial evidence to support the
hypothesis of involvement of a common carcinogenesis process for
both viral hepatitis associated-ICC and HCC. First, viral hepatitis B
and C were independent risk factors and the major cause for ICC
development. Our findings are consistent with that reported by
El-Serag et al (2009)recently. Through a population based cohort
study, El-Serag et al (2009) showed a strong association of HCC
and ICC with HCV infection, but the association was not observed
for extrahepatic cholangiocarcinoma. Second, as generally ob-
served in HCC, cirrhosis – a pathological result of long-term
chronic inflammation in the liver – exerted synergistic effects on
ICC development in patients of viral hepatitis B and C. Third, both
viral hepatitis-associated ICC and HCC had similar age profiles
and difference in age distributions between patients with chronic
hepatitis B and patients with chronic hepatitis C. Fourth, the ratio
of disease incidences for HCC:ICC:CHC was consistent with the
ratio of hepatocyte number to cholangiocyte number in the liver.
These findings strongly indicated the involvement of similar long-
term disease processes in the development of viral hepatitis-
associated ICC and viral hepatitis-associated HCC.
It is known that chronic infection, for example, because of
hepatitis B or C virus infection, plays a primary role not only in
trans-activating cellular proto-oncogenes and/or disrupting tu-
mour suppressor genes, but also in causing chronic inflammation.
Sustained cell proliferation in a micro-environment rich in
inflammatory cells, cytokines/chemokines, growth factors and
DNA-damaging agents (such as reactive oxygen and nitrogen
species because of long-term inflammation) will lead to permanent
genetic alterations and subsequent neoplastic transformation of
the proliferating cells (Komori et al, 2008). For example,
interleukin-6, an inflammatory cytokine, promotes human cho-
langiocarcinoma cells grown in vivo by inhibiting apoptosis
through the activation of miRNAs including miR let-7a and
miR370, thereby modulating the activation of STAT-3 pathways
(Meng et al, 2007, 2008; Smirnova et al, 2007). It has also been
shown that the sustained upregulation of the transcription factor
nuclear factor kappaB (NF-kB) in the liver cells, through the
paracrine action of tumour necrosis factor-a secreted from the
Table 5 Comparison of age at diagnosis amongst different groups of ICC
patients
ICC
Factors Case no. Age: Mean±s.d. P-value
HBsAg
+ 60 56.4±11.1 0.000*
  100 64.6±11.3
Anti-HCV
+ 21 65.6±9.17 0.096
  139 60.9±12.3
IHD stone
+ 59 64.9±11.8 0.005*
  101 59.5±11.7
Cirrhosis
+ 41 59.8±10.8 0.306
  119 62.1±12.3
All cases 160 61.5±12.0
Anti-HCV¼anti-hepatitis C virus antibody; HBsAg¼hepatitis B surface antigen.
+/–: seropositivity/seronegativity. *Po0.05 was considered significant (two-sample t-test).
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Figure 2 Comparison of disease incidence based on age distribution in
the 160 ICC patients and 2498 HCC patients. (A) Profiles for viral hepatitis
B patients with either HCC or ICC. (B) Profiles for viral hepatitis C patients
with either HCC or ICC. Interestingly, the age distribution profiles of
patients with viral hepatitis B and C are quite different in both ICC and
HCC, whereas the age distribution profiles between ICC and HCC patients
with either viral hepatitis B or C are nearly identical.
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tumour development (Maeda et al, 2005; Choi et al, 2006; Sakurai
et al, 2006; Luedde et al, 2007), given the activation of mitogenic
and anti-apoptotic genes through NF-kB pathways. In spite, the
hypothesis of sharing common disease process for the carcinogen-
esis of viral associated ICC and HCC remains to be verified using
cellular and animal models.
It has been known that men are about two–four times more
likely to develop HCC than women (Bosch et al, 2004). Recent
studies by using a chemical carcinogen (diethylnitrosamine) model
of HCC in mice showed that the gender disparity in HCC was
owing to suppression of interleukin-6 production in Kupffer cells
by oestrogen (Naugler et al, 2007). Our studies showed a more
prominence of gender disparity in HCC (male/female¼2.91, the
National Database, 2006) than in ICC (male/female¼1.31, based
on the National Database, 2006). In addition, the gender disparity
in both HCC and ICC was even more prominent in patients with
chronic hepatitis B (male/female¼5.04 in HCC or 2.16 in ICC)
than in patients with chronic hepatitis C (male/female¼2.35 in
HCC or 1.29 in ICC), suggesting that additional viral etiology and
environmental factors also contribute to the gender disparity in
both HCC and ICC development.
What are the target cells of chronic inflammation that induce
similar carcinogenic processes for ICC and HCC in chronic viral
hepatitis? Considering that tumour formation is a multi-step
process involving the accumulation of mutations over years or
even decades before the occurrence of neoplastic transformation,
the target cells should be able to proliferate as well as survive in the
liver for a long period. Some hepatocytes and bile duct cells
(cholangiocytes) can temporally proliferate, and act as the target
cells for carcinogenesis. The targeting of the proliferating
cholangiocytes in the liver could explain why chronic inflamma-
tion of bile ducts, such as that caused by sclerosing cholangitis,
hepatic fluke infection or hepatic lithiasis, is only associated with
cholangiocarcinoma but not HCC. However, these proliferating
cholangiocytes might not be the primary target cells for HCC
development in patients with viral hepatitis B and C, unless trans-
differentiation from the cholangiocyte to the hepatocyte lineage
occurs. Similarly, proliferating hepatocytes can be the target cells
for HCC. However, the requirement of a transitional differentiation
process from the hepatocyte to the cholangiocyte lineage makes it
less likely that viral hepatitis-associated ICC arises from the
proliferating hepatocytes. More likely is that viral hepatitis-
associated HCC and ICC are derived from the same cells of origin
that have the potential to develop into both the hepatocyte and
cholangiocyte lineages, and have long been exposed to the milieu
related to genome injury and consequently, tumour transforma-
tion (Alison, 2006; Libbrecht, 2006; Nomoto et al, 2006; Roskams,
2006; Zhang et al, 2008). Indeed, it is now generally believed that
cancer can originate from stem cells or progenitor cells rather than
from differentiated cells as these are the only cells that persist in
the tissue for a sufficient length of time to acquire the requisite
number of genetic changes for neoplastic transformation (Alison
and Lovell, 2005).
The speculation that both HBV- and HCV-associated HCC and
ICC are derived from liver progenitor cells (oval cells) is further
supported by the occurrence of CHC, in which both the
histological components of HCC and ICC are found simulta-
neously. Recently, it has been suggested that CHCs may arise from
hepatic progenitor cells that retain their potential to differentiate
into the hepatocytic and biliary lineages (Libbrecht, 2006; Zhang
et al, 2008).
Hepatic progenitor cells (oval cells), residing in the
canal of Hering in the liver, are multipotent progenitor cells that
can give rise to both hepatocytes and cholangiocytes. They
represent the replicating cellular compartment after liver injury.
The degree of reactivation of hepatic progenitor cells has been
associated with the degree of inflammatory activity in viral
hepatitis and cirrhosis (Roskams et al, 2003; Roskams, 2006).
Recently, cells with stemness properties have been identified in
human HCC, further supporting the speculation that hepatic
progenitor cells are involved in the carcinogenesis of HCC as well
as ICC (Barajas et al, 2007; Ma et al, 2007; Yamashita et al, 2007;
Zen et al, 2007; Qiao et al, 2008; Yang et al, 2008; Zhang et al,
2008).
The reason why the incidence of ICC in patients of viral hepatitis
B or C is substantially lower than that of HCC if both arise from the
same hepatic progenitor cells with a common pathogenic process
remains unknown. Our explanation is that the incidence of HCC vs
ICC is determined by the ratio of the number of the progenitor
cells differentiating into the two lineages hepatocytes vs cholan-
giocytes. Indeed, hepatocytes represent approximately 80–90% of
the liver cells, whereas bile duct cells account approximately 5–7%
of the liver cells. If this is the case, the incidence of
HCC:ICC:CHC should be approximately 225:15:1 (p:q:pq,
where p and q are the incidences for HCC and ICC, or the relative
numbers of hepatocytes and cholangiocytes in the liver, respec-
tively). Consistent with this estimation, the incidence of
HCC:ICC:CHC in our population was 233:17:1 (HCC:ICC:
CHC¼26543 cases:1949 cases:114 cases¼233:17:1) (according
to the Taiwan Cancer Registration System, 2003–2005) (http://
crs.cph.ntu.edu.tw). Further studies should be undertaken to
determine the roles and mechanisms of hepatic progenitor cells
in neoplastic transformation into HCC as well as ICC in patients of
viral hepatitis B or C.
We conclude that besides other causes of bile duct inflamma-
tion, viral hepatitis B and C are the primary independent risk
factors for ICC in our country, a viral hepatitis endemic area.
Cirrhosis exerts synergistic effects on ICC development in patients
of viral hepatitis B or C. Patients with viral hepatitis B developed
ICC B9 years earlier than patients with viral hepatitis C did. The
incidence of ICC by age distribution in patients with either viral
hepatitis B or C was nearly identical to that of HCC in patients with
viral hepatitis B or C. The ratio of the incidence of HCC to ICC to
CHC might reflect the ratio of the numbers of hepatocytes and
cholangiocytes differentiated from the same hepatic progenitor
cells. Our findings suggested that both viral hepatitis-associated
ICC and HCC originate from the same hepatic progenitor cells
through a similar long-term inflammatory carcinogenic process.
Our findings also suggest that all risk factors causing chronic
inflammation of the liver including chronic viral hepatitis,
inflammatory bile duct disease, hepatic lithiasis and hepatic
parasite infection could activate a common pathway for the
development of liver malignancy. Moreover, suppression of
inflammation may reduce cellular dysplasia, thereby preventing
malignancy.
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